Drug Trial Radar · NCT01227655
Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients.
Last checked: Nov 19, 2026Latest source record: Oct 19, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
427
Actual
Start
Mar 2011
Primary completion
Jul 2012
Study completion Jul 2012
Sponsor
- Lead sponsor
- Bial - Portela C S.A.Industry
- Sponsor type
- Industry
- First posted
- Oct 25, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 30 years, up to 83 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Parkinson's disease (PD) is a neurodegenerative disorder of unknown aetiology with an estimated incidence of 4.5-16/100,000 persons/year. BIA 9-1067 is currently being developed by BIAL (Portela \& Cª,S.A.) to be used in addition to L-DOPA (Levodopa) /carbidopa or L-DOPA (Levodopa) / preparations in PD patients. Promising results have been obtained for BIA 9-1067 in previous studies.
Conditions
- Parkinson's Disease
Interventions
BIA 9-1067Drug
Capsules will be used.
PlaceboDrug
comparator
LevodopaDrug
CarbidopaDrug
DOPA decarboxylase inhibitor (DDCI)
BenserazideDrug
DOPA decarboxylase inhibitor
Primary outcomes
What the sponsor says the trial is designed to measure.
- Efficacy of 2 BIA 9-1067 (25 mg, and 50 mg) Compared With Placebo, When Administered With the Existing Treatment of L-DOPA Plus a DDCI (DOPA Decarboxylase Inhibitor)Time frame: 14-15 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Bial - Portela & Cª, S.A.
S. Mamede Do Coronado, Portugal
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.